Summary of immune-modulating drugs and their targets
| Drug name | Drug target | Isotype | Source |
|---|---|---|---|
| Ipilimumab | CTLA-4 | IgG1 | Human |
| Nivolumab | PD-1 | IgG4 | Human |
| Pembrolizumab | PD-1 | IgG4 | Humanized |
| Atezolizumab | PD-L1 | IgG1 | Humanized |
| Durvalumab | PD-L1 | IgG1 | Human |
| Tremelimumab | CTLA-4 | IgG2 | Human |
| Avelumab | PD-L1 | IgG1 | Human |
| Utomilumab | CD137 | IgG2 | Human |
| INCAGN01876 | GITR | IgG1 | Humanized |
| INCAGN01949 | CD134 | IgG1 | Human |
| Rovalpituzumab Tesirine | DLL3 | IgG1 | Humanized |
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4, PD-1 programmed cell death protein-1, PD-L1 programmed death ligand-1, GITR Glucocorticoid-induced TNF-receptor-related protein